Amplification of EDHF-type vasodilatations in TRPC1-deficient mice

Br J Pharmacol. 2010 Dec;161(8):1722-33. doi: 10.1111/j.1476-5381.2010.00985.x.

Abstract

Background and purpose: TRPC1 channels are expressed in the vasculature and are putative candidates for intracellular Ca(2+) handling. However, little is known about their role in endothelium-dependent vasodilatations including endothelium-derived hyperpolarizing factor (EDHF) vasodilatations, which require activation of Ca(2+) -activated K(+) channels (K(Ca)). To provide molecular information on the role of TRPC1 for K(Ca) function and the EDHF signalling complex, we examined endothelium-dependent and independent vasodilatations, K(Ca) currents and smooth muscle contractility in TRPC1-deficient mice (TRPC1-/-).

Experimental approach: Vascular responses were studied using pressure/wire myography and intravital microscopy. We performed electrophysiological measurements, and confocal Ca(2+) imaging for studying K(Ca) channel functions and Ca(2+) sparks.

Key results: TRPC1 deficiency in carotid arteries produced a twofold augmentation of TRAM-34- and UCL1684-sensitive EDHF-type vasodilatations and of endothelial hyperpolarization to acetylcholine. NO-mediated vasodilatations were unchanged. TRPC1-/- exhibited enhanced EDHF-type vasodilatations in resistance-sized arterioles in vivo associated with reduced spontaneous tone. Endothelial IK(Ca) /SK(Ca)-type K(Ca) currents, smooth muscle cell Ca(2+) sparks and associated BK(Ca)-mediated spontaneous transient outward currents were unchanged in TRPC1-/-. Smooth muscle contractility induced by receptor-operated Ca(2+) influx or Ca(2+) release and endothelium-independent vasodilatations were unaltered in TRPC1-/-. TRPC1-/- exhibited lower systolic blood pressure as determined by tail-cuff blood pressure measurements.

Conclusions and implications: Our data demonstrate that TRPC1 acts as a negative regulator of endothelial K(Ca) channel-dependent EDHF-type vasodilatations and thereby contributes to blood pressure regulation. Thus, we propose a specific role of TRPC1 in the EDHF-K(Ca) signalling complex and suggest that pharmacological inhibition of TRPC1, by enhancing EDHF vasodilatations, may be a novel strategy for lowering blood pressure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Alkanes / pharmacology
  • Animals
  • Biological Factors / physiology*
  • Blood Pressure / drug effects
  • Calcium Signaling / drug effects
  • Calcium Signaling / physiology
  • Carotid Arteries / drug effects
  • Carotid Arteries / physiology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiology
  • Female
  • Male
  • Mice
  • Mice, Knockout
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / physiology
  • Nitric Oxide / pharmacology
  • Potassium Channels, Calcium-Activated / drug effects
  • Potassium Channels, Calcium-Activated / physiology
  • Pyrazoles / pharmacology
  • Quinolinium Compounds / pharmacology
  • TRPC Cation Channels / genetics
  • TRPC Cation Channels / physiology*
  • Vasodilation / genetics
  • Vasodilation / physiology*
  • Vasodilator Agents / pharmacology

Substances

  • 6,10-diaza-3(1,3),8(1,4)dibenzena-1,5(1,4)diquinolinacyclodecaphane
  • Alkanes
  • Biological Factors
  • Potassium Channels, Calcium-Activated
  • Pyrazoles
  • Quinolinium Compounds
  • TRAM 34
  • TRPC Cation Channels
  • Vasodilator Agents
  • endothelium-dependent hyperpolarization factor
  • transient receptor potential cation channel, subfamily C, member 1
  • Nitric Oxide
  • Acetylcholine